Atle T.
- Country
- Norway
- Department
- Pulmanory Medicine Department
Research Overview
- Evaluation of Thoracic Radiotherapy Combined with Durvalumab and Chemotherapy in Extensive-Stage Small-Cell Lung Cancer: A Randomized Phase III Trial
- Phase 2 Study on the Efficacy of Alpelisib and Drug Combinations in Advanced Cancer with Genomic or Protein Expression Variants in Norway
- Evaluation of Dabrafenib, Trametinib, and Imatinib in the Treatment of Rare and Hard-to-Treat Cancers: A Clinical Trial on Drug Repurposing
Data & Insights
Has run more than one trial at 17 of 27 partner sites.
Specializations
Lung Cancer Specialization
The investigator focuses on advancing treatment approaches for extensive stage small-cell lung cancer, particularly exploring innovative combination therapies that integrate thoracic radiotherapy with immunotherapy and chemotherapy.
- Combined treatment modalities
- Survival outcome optimization
- Advanced stage lung cancer management
Their research emphasizes improving survival outcomes through multimodal therapeutic approaches.
Precision Medicine Implementation
The investigator specializes in implementing precision medicine in public cancer care, focusing on evaluating targeted anti-cancer drugs and their efficacy based on specific genomic and protein expression variants.
- Genomic-guided therapy
- Drug target identification
- Treatment personalization
Their work aims to enhance patient access to targeted therapies in advanced malignancies.
Rare Cancer Treatment
The investigator concentrates on developing treatments for rare and hard-to-treat cancers, with particular emphasis on drug repurposing strategies and evaluating the effectiveness of existing targeted therapies.
- Novel drug applications
- Treatment optimization
- Toxicity monitoring
Their research focuses on expanding treatment options for challenging cancer cases.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.